Brandon Sklenar And Julia Schlaepfer Hid Oranges In Their Pockets For The Elephants On 1923
Learn More Brandon Sklenar And Julia Schlaepfer Hid Oranges In Their Pockets For The Elephants On 1923 "1923," like many westerns before it, gives viewers panoramic shots of horses grazing on wheat-fruited plots of land. But the "Yellowstone" spin-off has also taken audiences to a surprising place…#learnmore #brandonsklenar #elephants #african #spencerdutton #worldwarispencer #africa #worldwari #greatdepression #spencer (Source: Reuters: Health)
Source: Reuters: Health - January 28, 2023 Category: Consumer Health News Source Type: news
Pitch Deck Teardown: Orange ’s $2.5M seed deck
Earlier this week, I wrote a story about EV charging company Orange and how it is taking a different approach to putting chargers everywhere. Instead of a few high-speed chargers, it makes it easy for multifamily dwellings (think apartment buildings) to put charger sockets everywhere there might…#orange #slides #cover #orangechargings #slide #oranges #photoshop #orangechargers #teslas #240v (Source: Reuters: Health)
Source: Reuters: Health - January 26, 2023 Category: Consumer Health News Source Type: news
Do you smell what I smell? How scents linked to Christmas have changed
While oranges and cloves moved from medicine cabinet to kitchen, rosemary fell out of festive fashion in EnglandThe waft of pine trees and cinnamon biscuits may mean it is beginning to smell a lot like Christmas, but the odours that conjure up yuletide today may not always have had such joyful connotations, research has revealed.Experts studying records of smells described in texts dating as far back as the 16th century say they have discovered the scents we associate with Christmas have shifted over time.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - December 24, 2022 Category: Science Authors: Nicola Davis Science correspondent Tags: Christmas Science Heritage UK news Source Type: news
Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib). These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Twin hurricanes just decimated what was left of Florida's orange crop
Twin hurricanes just decimated Florida’s orange crop Production of oranges in Florida this season is forecast to be down 36% from earlier estimates, in part a reflection of twin hurricanes that battered growing regions, according to U.S. Agriculture Department figures released Friday. The latest…#mattjoyner #worldwarii #floridacitrusmutualtradeassociation #usbureauoflaborstatistics #floridaagriculture #nikkifried #brazil #universityofflorida #usagriculturedepartment #floridian (Source: Reuters: Health)
Source: Reuters: Health - December 9, 2022 Category: Consumer Health News Source Type: news
Mulled wine could lower high cholesterol by 12% but how much you drink matters
"All spices and citrus fruits including oranges, lemons, cinnamon, nutmeg, ginger, and cloves are welcomed when making your own mulled wine as these are all delicious flavours for the ultimate festive drink," a wellness expert said. (Source: Daily Express - Health)
Source: Daily Express - Health - December 4, 2022 Category: Consumer Health News Source Type: news
Citrus Disease Decimating Florida Oranges Stalks Brazil's Crop
Citrus Disease Decimating Florida Oranges Stalks Brazil's Crop Bloomberg#citrusdiseasedecimatingfloridaorange #cropbloomberg #brazil (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2022 Category: Consumer Health News Source Type: news
Study: Eating a serving of dark, leafy greens daily may slow memory decline
People who eat and drink more foods with flavonols -- found in certain fruits and vegetables, including kale, tomatoes, apples and oranges, plus tea and wine -- may have slower memory decline in older age, a study says. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 22, 2022 Category: Consumer Health News Source Type: news
Zanab Jaffrey From " Love Is Blind " Responded Following The Oranges Controversy
"One thing about me, I choose my words carefully and I stand by everything I said." #loveisblind #zanabjaffrey (Source: Reuters: Health)
Source: Reuters: Health - November 10, 2022 Category: Consumer Health News Source Type: news
Six-year-old boy's skin turns YELLOW because he eats so many oranges
While children are always encouraged to eat fruit and vegetables for one six-year-old in Devon a healthy habit led to them developing a bizarre Simpons-esque yellowing of their skin. (Source: the Mail online | Health)
Source: the Mail online | Health - October 5, 2022 Category: Consumer Health News Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
‘CubeSats are not toys.’ Tiny satellites’ scientific output can pack a big punch
Orbiting several hundred kilometers above the planet are two satellites, each the size of a half-loaf of bread, measuring bursts of light-speed electrons that sometimes rain into the atmosphere. When researchers first launched them in 2015, they had hoped the little satellites would last 3 months before they malfunctioned. More than 7 years later, they are still transmitting information about the variation in and location of the electron bursts—and the team has 19 published papers to show for the $1.2 million mission, called FIREBIRD II. The success of FIREBIRD II and missions like it are changing the way scientist...
Source: ScienceNOW - July 8, 2022 Category: Science Source Type: news
New IMBRUVICA ® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Updated data from the FD cohort with three years of follow-up shows that I+V continues to demonstrate deep and durable responses and clinically meaningful progression-free survival (PFS) and overall survival (OS) in the first-line tre...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Phase 3 SHINE Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
This study is one of the largest clinical trials ever conducted in first-line MCL and the first for a Bruton’s tyrosine kinase inhibitor (BTKi). The data are being presented in an oral session and featured in a press briefing during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, and were published in The New England Journal of Medicine today. The data will also be presented as an oral presentation at the 2022 European Hematology Association (EHA) Annual Congress. MCL is a type of aggressive, rare non-Hodgkin lymphoma (NHL) that is incurable and difficult to treat. It commonly affects people o...
Source: Johnson and Johnson - June 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news